Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06934642 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effect of Tirzepatide on Markers of MASLD in Patients With Obesity

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 31 days later Aug 2026 → Oct 2026
See other at-risk trials from University of New Mexico

Record History

  1. Primary and study completion pushed from Aug 2026 to Oct 2026v5
  2. Re-verified, no change to tracked fieldsv4
  3. Start date changed from estimate of Jun 2025 to Jun 30, 2025v3
  4. Primary and study completion dates: Jun 2026 to Aug 2026 Start date: May 2025 to Jun 2025v2 Show 1 more changeShow less
    • Start date: May 2025 to Jun 2025
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
University of New Mexico
46 trials monitored
See 9 trials at risk
Obesity
3,560 trials monitored
See 142 trials at risk
NASH / MASH
654 trials monitored
See 22 trials at risk
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is the most common cause of chronic liver disease worldwide and predominately affects individuals with overweight and obesity, as well as those with type 2 diabetes and cardiovascular disease. Tirzepatide is a medication used to treat type 2 diabetes and obesity. It has also been shown to help with MASLD. The purpose of this study is to study how tirzepatide affects the liver in patients with MASLD. Participants will be asked to: * Take tirzepatide for 12 months. * Come in for clinic visits every 3 months. * Have blood drawn at baseline, 6, and 12 months. * Complete a liver ultrasound at baseline and at 12 months.
Trial Details
NCT Number NCT06934642
Lead Sponsor University of New Mexico
Collaborators: American Cancer Society, Inc., University of New Mexico Cancer Center
Conditions MASLD, Obesity
Enrollment 8 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov